You just read:

Data Presented at the International Society of Paediatric Oncology (SIOP) Congress Show Palonosetron is a Valuable Option for Treating Pediatric Patients Receiving Moderately to Highly Emetogenic Chemotherapy

News provided by

Helsinn Healthcare Group

23 Oct, 2014, 14:30 BST